Compare Davita Inc (DVA) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nasdaq100 ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Nasdaq100 ETF trades at $753.15 (market cap $506.92B). The key difference: Nasdaq100 ETF is far larger — about 44.9× Davita Inc's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Nasdaq100 ETF for 162 Days on average.
| DVA | QQQ | |
|---|---|---|
Market Cap | $11.29B | $506.92B |
Volume | 582,204 | 48,326,518 |
Sector | Health | — |
52-Week High | $240.96 | $759.66 |
52-Week Low | $103.87 | $558.34 |
Typical Hold Time | 113 Days | 162 Days |
Enterprise Value | $24.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
QQQ trades at $757.73, down 0.25% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights comparisons with lower-fee alternatives like QQQM and VOO, while broader market concerns about AI valuations and interest rate impacts create headwinds.
The outlook for QQQ remains tied to technology sector performance and AI-driven growth, though elevated valuations and concentration risk warrant caution. Near-term support lies at $754, with resistance at $760. Investors face balancing growth potential against fee differentials and market volatility risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
